|

mFOLFIRINOX Clinical Trials

14 actively recruiting trials across 8 locations

No change since May 2026

Pipeline

Phase 1: 4Phase 2: 5Phase 1/2: 2Phase 2/3: 3

Top Sponsors

  • Zhejiang University1
  • Washington University School of Medicine1
  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1
  • Tango Therapeutics, Inc.1
  • Oncotelic Inc.1

Indications

Other6 trials

A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
Phase 2
Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer
Phase 2/3
Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer
Phase 1/2
Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients
Phase 2
Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
Phase 2
Preoperative Radiotherapy And ASTX660 in Rectum Cancer
Phase 1

Birmingham, Alabama1 trial

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

University of Alabama at Birmingham Cancer Center

Phase 2/3

Phoenix, Arizona1 trial

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Mayo Clinic Hospital

Phase 1

Scottsdale, Arizona1 trial

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Mayo Clinic Scottsdale

Phase 1/2

Los Angeles, California1 trial

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

USC Norris Comprehensive Cancer Center

Phase 2

New Haven, Connecticut1 trial

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

Yale University School of Medicine

Phase 1

Detroit, Michigan1 trial

A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

Karmanos Cancer Center

Phase 2/3

St Louis, Missouri1 trial

MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Washington University School of Medicine

Phase 1

Houston, Texas1 trial

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

MD Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.